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S338 Poster Session IIResults:A single dose of pre-emptive ECP treated splenocytes led to
a significant survival benefit (median survival 27 versus 52 days, p\
0.0001). Re-isolation experiments on day 7 after BMT showed an in-
crease in host Treg in peripheral and mesenteric lymph nodes,
whereas donor Treg were similar in both groups. However, Tcon
proliferation was not significantly impacted, as quantified by BLI.
Using pulsed BrdU labeling no proliferation of host Treg was seen
after transplantation. Also, intracellular staining and analysis of
serum cytokine levels to characterize Th1/Th2 polarization of T
cells revealed no differences at day 7. Importantly, preliminary
experiments showed no alteration in graft versus tumor effect. In
summary, a single dose of apoptotic cells prior to transplantation
led to a significant survival benefit. Whether this effect is related
to the relative sparing of host-Tregs remains to be determined.
However, the mechanism does not appear to be related to reduced
T cell proliferation. Other avenues to be explored include further
studies of cellular mechanism, e.g. maturation status of host APC,
as well as evaluating multiple administration doses to further
improve outcome. Pre-emptive ECP of host cells prior to BMT
may be a clinically relevant strategy to ameliorate acute GvHD.516
GENE EXPRESSION IN CD4+ T CELLS OF PATIENTSWITH ANDWITHOUT
CHRONIC GRAFT-VS-HOST DISEASE (CGVHD)
Tabellini, L.1, Fan,W.1, Zhao, L.P.1, Bumgarner, T.E.1, Flowers, M.E.1,
Grogan, B.M.1, Warren, H.E.1,2, Lee, S.J.1,2, Martin, P.J.1,2,
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The biologic processes underlying cGVHD and the development
of clinical tolerance are unknown. We tested whether gene expres-
sion in CD4+T cells can distinguish between patients with and with-
out active cGVHD. CD4+ T cells from 69 patients and 22 normal
volunteers were isolated by negative selection and RNA analyzed
using Illumina RefSeq8 arrays. Thirty-one patients were tolerant
(defined as free of any chronic GVHDwithout immune suppression
therapy {IST} for at least 6 months), and 38 patients had active
cGVHD (14 with and 22 without IST). A hierarchical clustering
analysis of differentially expressed genes separated the 31 tolerant
patients into 2 groups, and an analysis of clinical covariables demon-
strated that they differed primarily by interval time from HCT (1-5
yrs, and 5-16 yrs). Differential expression was observed for 1148
genes in cGVHD patients, 902 genes in 18 tolerant patients at 1-5
yrs after HCT, and 186 genes in 13 tolerant patients at 5-16 yrs after
HCT compared to controls. We found substantial overlap in the
genes differentially expressed in cGVHD and tolerant groups, espe-
cially early after HCT. The shared cGVHD-tolerant profile was
characterized by activation of NF-kB-associated and IFN-inducible
genes, and upregulation of Th1 pathways. The differentially ex-
pressed genes uniquely associated with the early tolerance after
HCT were associated mainly with protein biosynthesis and metabo-
lism. We found no differential expression of TGFB-associated
genes, IL10 or FOXP3. Fewer genes were differentially expressed
in the late tolerant group compared to the early tolerant group
(186 vs 902), with no consistent qualitative difference in the associ-
ated functions of these genes in late vs. early tolerant profiles. In
summary, in this CD4+ T cell gene expression dataset, we found
no evidence for an expression profile unique to tolerant patients.
The number of genes differentially expressed in tolerant patients re-
turned toward normal over time, but differential expression relative
to age-matched normal controls continued as late as 15 years after
HCT. Future expression studies in function-defined CD4+ T cell
subsets or Tregmay yet provide insight into themechanisms respon-
sible for development of immunological tolerance after HCT.517
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Background: Recently, a growing body of evidence has suggested
that adiponectin, which is secreted by adipose tissues, plays a critical
role in obesity-related and autoimmune diseases. However, the roles
of adiponectin in allogeinc stem cell transplantation remains un-
known. Therefore, we compared the serum adiponectin levels
among allo-SCT recipients and normal subjects to assess the associ-
ation between adiponectin and cGVHD.
Patients and methods: We compared the concentrations of high-
molecular-weight (HMW) adiponectin among 26 normal subjects
and 35 allogeneic stem cell transplantation recipients by an en-
zyme-linked immunosorbent assay. To compareHMW-adiponectin
levels among groups, we used the first samples obtained at least 6
months after SCT. Furthermore, we calculated the ratios of
HMW-adiponectin between each pair of consecutive samples in
the same patients, and assessed the impact of the clinical changes
in cGVHD on HMW-adiponectin concentrations among recipients
grouped according to worsening, stable, and improving cGVHD.
Results: The serum concentrations of HMW-adiponectin in
healthy subjects and recipients without chronic graft-versus-host-
disease (cGVHD), with limited cGVHD, and with extensive
cGVHD were 8.766.5, 10.664.2, 19.1610.7 and 25.969.9 mg/ml
in females (P 5 0.0011), and 3.661.8, 5.364.1, 6.466.7 and
9.966.1mg/ml in males (P 5 0.039). Multivariate analysis revealed
that a higher concentration of adiponectin was associated with fe-
male gender (P \ 0.0001) and the presence of cGVHD (P 5
0.0026 and\0.0001 in limited and extensive cGVHD, respectively).
In addition, HMW-adiponectin levels increased as cGVHD pro-
gressed, decreased as cGVHD improved, and did not change with
stable cGVHD.
Conclusion:HMW-Adiponectin was associated with the severity of
cGVHD, and might play a role in the pathophysiology of
cGVHD.Further investigation is warranted.518
ATG FOR THE PREVENTION OF SEVERE ACUTE GRAFT-VERSUS-HOST
DISEASE IN MISMATCHED UNRELATED DONOR HEMATOPOIETIC CELL
TRANSPLANTATION
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Tate, C., Locke, F., Fernandez, H., Anasetti, C. Moffitt Cancer Center,
Tampa, FL
Severe (grade III-IV) acute GVHD remains a major source of
morbidity and mortality following mismatched unrelated donor he-
matopoietic cell transplantation (HCT). As donor alloreactive T
cells are principal mediators of the syndrome, in vivoT cell depletion
by anti-lymphocyte antibodies may offer additional protection
against severe aGVHD. We have developed a regimen of anti-thy-
mocyte globulin (ATG) 7.5mg/kg total (1m/kg day -3, and
3.25mg/kg on days -2 and -1) to both minimize toxicity from oppor-
tunistic infections and optimize efficacy in aGVHD prevention. We
identified a consecutive series of 6-7/8 mismatched (at loci A, B, C,
DR) unrelated donor HCT recipients treated with 7.5mg/kg total
(1mg/kg given day -3, then 3.25mg/kg/day on days -2 and -1) rabbit
ATG in concert with calcineurin inhibitor-based pharmacologic
GVHD prophylaxis prior to stem cell infusion. Forty-five subjects
were included in this analysis; seven subjects treated with this regi-
men were excluded, given sole mismatch at DQ (n5 4) or 8/8 match
(n 5 3). Median age of subjects was 48 (range 22 – 67). There was
disparity at heterogeneous HLA loci between recipient and donor,
including mismatch at one locus in 43 cases and two loci in 2 cases.
There were no cases of primary engraftment failure. Neutrophil
(median 15 days, range 11 – 25) and platelet (median 16 days, range
7 – 31) engraftment were not delayed. The cumulative incidence of
grade III-IV acute GVHD was 11% by 100 days (95% CI 5 –
25%). Moderate to severe chronic GVHD (per NIH criteria) was
19% (95% CI 10 – 36%) at one year, and 28% (95% CI 16 –
48%) at 2 years. With a median follow up of 12 months (range 5 –
39 months), overall survival was 55% (95% CI 39 – 71%) at one
year, and 45% (95%CI 27 – 63%) at two years. Non-relapse mortal-
ity was 11% (95% CI 5 – 25%) by 100 days post-HCT, and 26%
Poster Session II S339(95% CI 16 – 44%) by one year. The cumulative incidence of pri-
mary disease relapse was 23% (95% CI 13 – 41%) at 1 year. CMV
reactivation differed according to recipient and donor CMV
serostatus. EBV reactivation occurred in 54% (95% CI 40% -
71%). Preemptive rituximab therapy controlled EBV in the majority
of cases; however, PTLD was diagnosed in 5 cases, and was fatal in
one. A regimen of ATG 7.5mg/kg today ending on day -1 effectively
prevents grade III-IV acute GVHD and severe chronic GVHD in
6-7/8 mismatched unrelated donor HCT.519
INFLUENCE OF GENOMIC STRUCTURAL VARIANTS ON GVHD AND RE-
LAPSE RISK IN LYMPHOMA PATIENTS TREATED WITH ALLOGENEIC
HSCT
Larson, G.P.1, Palmer, J.2, Qian, D.2, Forman, S.3, Senitzer, D.4,
Nakamura, R.3 1Beckman Research Institute of the City of Hope, Duarte,
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Copy number variants (CNV) contribute to the risk of multiple
common diseases and are implicated in unfavorable clinical out-
comes in HSCT. The role of CNVs bearing immuno-tolerance
genes (mHAg) has been demonstrated for UGT2B17 in HLA-
matched siblings after HSCT (McCarroll, et alNat Genet 2009). Ho-
mozygous CNV deletion trans€ıplant donors mismatched with
CNV+ recipients may harbor immune systems na€ıve to proteins
present within the recipient eliciting GVHD demonstrating a grow-
ing role for CNVs in transplant medicine. Allogeneic HSCT, a po-
tentially curative therapy for recurrent non-Hodgkin lymphoma
(NHL), is often compromised by transplant-mediated GVHD
thereby jeopardizing patient survival. Owing to known differences
in CNV allele frequencies in ethnically diverse populations com-
bined with the racially diverse composition of NHL patients seen
at our institution, the incidence of CNV-mediated GVHD may
very widely. To test this premise, we are examining the affect of pop-
ulation-specific CNVs on GVHD in a cohort of NHL patients.
We are investigating GVHD in 292 patients who underwent
HSCT to 1) determine the genetic admixture of our patients, 2) sub-
sequently use genetic ancestry to guide the selection of CNVs for
GVHD association testing, and 3) develop a novel mass spectrome-
try based platform to genotype CNVs. In our initial group of 85 pa-
tients who underwent allo-HSCT (64 related and 21 unrelated
donors), grade II-IV acute GVHD occurred in 43 patients, and 21
experienced NHL relapse. Forty-eight patients self-reported as
non-Hispanic Caucasian, 3 African American, 5 Asian, and 29 His-
panic or Latino. Genetic admixture estimates with a panel of 100
Ancestry Informative Markers were used to define genetic ancestry
and correlate to self-reported ethnicity. Admixture analysis on self-
reported Hispanics showed that 69% (20/29) contained. 10% Am-
erIndian ancestry. Weighted ancestry estimates in 3 HapMap popu-
lations based on genetic proportions observed in our patients
indicate numerous CNV alleles as potential targets, 48 of these
have allele frequencies . 10% in our cohort and represent possible
targets for donor-recipient mismatches.
We are genotyping donor/recipient pairs for a select group of
CNVs in conjunction with UGT2B17 using mass spectroscopy to
correlate CNV discordant pairs with GVHD. Approaches like this
are applicable to the racially diverse patient populations commonly
seen at institutions performing HSCT and may improve clinical
outcomes.520
A PHASE I/II STUDY OF CHEMOTHERAPY FOLLOWED BY DONOR LYM-
PHOCYTE INFUSION PLUS INTERLEUKIN-2 FOR RELAPSED ACUTE LEU-
KEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Inamoto, Y., Fefer, A., Sandmaier, B.M., Gooley, T.A., Warren, E.H.,
Petersdorf, S.H., Sanders, J.E., Storb, R.F., Appelbaum, F.R.,
Martin, P.J., Flowers, M.E.D. Fred Hutchinson Cancer Research Center,
Seattle, WA
Introduction: Efficacy of donor lymphocyte infusion (DLI) for
relapsed acute leukemia after allogeneic hematopoietic cell trans-
plantation (HCT) is limited. We hypothesized that interleukin-2
(IL-2) combined with DLI after chemotherapy might augmentgraft-versus-leukemia effects. To identify a safe and effective IL-2
regimen, a phase I/II study of DLI plus IL-2 therapy was performed.
Methods: Patients with relapsed acute myeloid leukemia (AML) or
acute lymphoblastic leukemia (ALL) after allogeneic HCT were el-
igible for this study. After chemotherapy, patients received DLI
(1x108 CD3/kg for patients with related donors, and 0.1x108 CD3/
kg for those with unrelated donors) and an escalating dose of induc-
tion IL-2 (Aldesleukin, Chiron, CA; 1.0, 2.0, or 3.0x106 IU/m2/day
representing levels I, Ia and II) for 5 days followed by maintenance
(1.0x106 IU/m2/day) for 10 days as a continuous intravenous infu-
sion. Study toxicities were prespecified. An excess study toxicity
rate was defined as any incidence where the lower limit of the 80%
one-sided confidence interval exceeded 25%. To examine the poten-
tial efficacy of this therapy, disease-free survival (DFS) was estimated
according to diagnosis and remission status at time of DLI.
Results:Atotalof17patients(11withAMLand6withALL)withmedian
age33years(range19-61)wereenrolledinthisstudy.Donorswererelated
siblingsfor13patientsandunrelatedvolunteersfor4patients.Sixteenpa-
tientshadapriorhistoryofGVHD.ThemediantimefromHCTtoche-
motherapy was 11.8 months (range 3-121). The median time from
chemotherapytoDLIwas61days(range36-91).Outcomesaresumma-
rizedintheTable.IL-2relatedtoxicitieswerereversibleinallexceptin1
patientatlevelIIwhodiedofcapillaryleaksyndrome.GradesIII-IVacute
GVHDdevelopedin5patients,andextensivechronicGVHDdeveloped
in8.Studytoxicitiesdevelopedin1patientatIL-2doselevelI,2patientsat
levelIaand1patientat levelII.Eightpatientshadacompleteremission
afterchemotherapypriortoDLI,and2additionalpatientshadacomplete
remissionafterDLIplusIL-2therapy.DFSat1yearwas40%forpatients
withAMLincomplete remissionatDLI (n55) and8%for thosewith
AMLnotinremission(n56)orALLinanystageatDLI(n56).
Conclusion: The maximal tolerated induction dose of IL-2 com-
bined with DLI appears to be 1.0x106 IU/m2/day. IL-2 administra-
tion after DLI might increase the incidence of chronic GVHD.
Table 1. GVHD, study toxicity and remission duration after
DLI according to IL-2 dose level
RemissionPatient# DiagnosisIL-2 Dose
LevelAcute
GVHDChronic
GVHDStudy
Toxicity*Duration after
DLI (Month)1 AML I 0 NA N 02 AML I III Extensive N 333 AML I III Extensive N 354 AML I 0 Extensive N 05 ALL I 0 0 N 06 ALL I III Extensive Y (GVHD) 87 ALL I 0 0 N 58 AML Ia 0 NA N 09 AML Ia 0 0 N 010 AML Ia II Extensive N 911 AML Ia 0 Extensive N 512 AML Ia IV Extensive Y (GVHD) 4713 AML Ia 0 0 N 614 AML Ia 0 0 N 315 ALL Ia 0 Limited N 016 ALL Ia III Extensive Y (IL-2) 1217 ALL II 0 NA Y (IL-2) 0*Death related to acute or chronic GVHD, development of acute or
chronic GVHD with inability to decrease the dose of prednisone to
less than 1mg/kg/day within 1 month after initiating treatment for
GVHD, or life threatening or fatal organ toxicity attributable to IL-2.521
INTERFERON-GAMMA PRODUCTION BY ALLOGENEIC FOXP3+ REGULA-
TORY T CELLS PROMOTES SURVIVAL IN EXPERIMENTAL GVHD
Koenecke, C.1,2, Lee, C.-W.1,2, F€ohse, L.2, Ganser, A.1, F€orster, R.2,
Prinz, I.2 1Hannover Medical School, Hannover, Germany; 2Hannover
Medical School, Hannover, Germany
Background and Aims:Adoptive transfer of natural FoxP3+ regula-
tory T cells (Tregs) has been shown to prevent lethal GvHD. It is
emerging that Tregs are a stable lineage that do not revert into harm-
ful FoxP3 effector cells. However, we have recently found that Tregs
